Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy

National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin

(2010) Nadine Shehab et al.   ARCHIVES OF INTERNAL MEDICINE

Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome

(2010) Xiu-ren Gao et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

(2010) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

(2010) Shamir R Mehta et al.   LANCET

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

PGE2 decreases reactivity of human platelets by activating EP2 and EP4

(2010) James P. Smith et al.   THROMBOSIS RESEARCH

Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk

(2009) Marie Therese Cooney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New P2Y12blockers

(2009) M. CATTANEO   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy

(2009) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

(2009)   LANCET

Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges

(2009) C. Patrono et al.   MOLECULAR INTERVENTIONS

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of clopidogrel on “aspirin specific” pathways of platelet inhibition

(2009) Alex R. Hobson et al.   PLATELETS

Prostaglandin F2  elevates blood pressure and promotes atherosclerosis

(2009) Y. Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of “Nuisance” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation

(2008) Probal Roy et al.   AMERICAN JOURNAL OF CARDIOLOGY

Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases

(2008) Patricia McGettigan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antiplatelet Drugs

(2008) Carlo Patrono et al.   CHEST

Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding

(2008) Tracy Y. Wang et al.   CIRCULATION

Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation

(2008) Eric Arehart et al.   CIRCULATION RESEARCH

The Gi-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets

(2008) Gianni F. Guidetti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease

(2008) Charles H. Hennekens et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?

(2008) Nina Zidar et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

(2008) Timothy D Warner et al.   LANCET

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial

(2008) Stephen D Wiviott et al.   LANCET

DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

(2008) Stan Heptinstall et al.   PLATELETS

Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways

(2007) Ruba S. Deeb et al.   HYPERTENSION